Biotelemetry Inc (BEAT)
$35.61 2.90 (7.53%)
11:18 EDT BEAT Stock Quote Delayed 20 Minutes
Previous Close $38.51
Market Cap 1.17B
PE Ratio -96.24
Volume (Avg. Vol.) 183,089
Day's Range 31.24 - 37.68
52-Week Range 27.35 - 63.24
Dividend & Yield N/A (N/A)
BEAT Stock Predictions, Articles, and Biotelemetry Inc News
- From InvestorPlace
- From the Web
Here are some triple-a stocks to buy that are primed to start the new year going strong.
As potential impacts from the trade war with China loom, these stocks to buy are far more prepared to weather the storm.
We shortlist four solid stocks that have striking earnings growth and positive estimate revisions. Compare Brokers....
The tone of trade is a definitive "risk on" with equities rallying, Treasury bonds pulling back and overall market breadth strong. The action in small-cap stocks has been particularly impressive, with the Russell 2000 set to cap a five-day winning streak.
With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.
From Market News Video
Investors in BioTelemetry Inc (BEAT) saw new options begin trading this week, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
To the annoyance of some shareholders, BioTelemetry (NASDAQ:BEAT) shares are down a considerable 41% in the last month. That drop has capped off a tough year for shareholders, with the<div><a class="permalink" href="https://simplywall.st/stocks/us/healthcare/nasdaq-beat/biotelemetry/news/how-does-biotelemetrys-nasdaqbeat-p-e-compare-to-its-industry-after-the-share-price-drop/">Read More...</a></div>
Legendary fund manager Li Lu (who Charlie Munger backed) once said, ‘The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of<div><a class="permalink" href="https://simplywall.st/stocks/us/healthcare/nasdaq-beat/biotelemetry/news/we-think-biotelemetry-nasdaqbeat-can-stay-on-top-of-its-debt/">Read More...</a></div>
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We’ll show how you can use BioTelemetry, Inc.’s (NASDAQ:BEAT) P/E ratio to<div><a class="permalink" href="https://simplywall.st/stocks/us/healthcare/nasdaq-beat/biotelemetry/news/what-does-biotelemetry-inc-s-nasdaqbeat-p-e-ratio-tell-you/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader